Detalhe da pesquisa
1.
The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures.
Front Pharmacol
; 11: 591134, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-33519450
2.
Policies for biosimilar uptake in Europe: An overview.
PLoS One
; 12(12): e0190147, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-29284064